Skip to search formSkip to main contentSkip to account menu

betrixaban

An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Betrixaban is primarily excreted unchanged in… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzamidesPyridines

Narrower (1)

PRT054021

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients
The main advantage of understanding aetiological risks for any condition is that their recognition allows early targeted… 
2017
2017
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial
Abstract Background The aim of this study was to evaluate the effect of betrixaban on the occurrence of deep vein thrombosis (DVT… 
2017
2017
Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial
Hospitalized acute medically ill patients with a history of venous thromboembolism (VTE) are at increased risk for recurrent VTE… 
2017
2017
The safety and efficacy of full‐ versus reduced‐dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended‐Duration Betrixaban (APEX) trial
2015
2015
Antidotes progress for new oral clotbusters
2012
2012
Metabolism and Disposition of Betrixaban and Its Lack of Interaction with Major CYP Enzymes.
Abstract 2266 Betrixaban is a once daily oral Factor Xa inhibitor being investigated in a Phase 3 clinical trial to prevent… 
Review
2011
Review
2011
Optimization of Anticoagulation with Warfarin for Stroke Prevention: Pharmacogenetic Considerations
Warfarin is a cornerstone of oral anticoagulation for stroke prevention. Anticoagulation with warfarin in patients with atrial… 
2010
2010
New anticoagulants and the future of cardiology.
Review
2009
Review
2009
Factor Xa inhibitors
Summary Oral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest… 
Highly Cited
2008
Highly Cited
2008
Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors.
Abstract Individuals anticoagulated with warfarin or heparin are typically treated with specific antidotes such as vitamin K or… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)